Jaksch Frank JR Buys Shares of Niagen Bioscience
On June 24, 2026, Jaksch Frank JR bought 31,746 shares of Niagen Bioscience.
Key Points
- Jaksch Frank JR purchased 31,746 shares of Niagen Bioscience, Inc. on June 24, 2026.
- Niagen Bioscience, Inc. traded near $3.42 on Saturday with a market cap of $272.4 million.
- Analysts from HC Wainwright & Co. and Canaccord Genuity maintained buy ratings with targets up to $14.0.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jaksch Frank JR bought 31,746 shares of Niagen Bioscience, Inc. (NasdaqCM: NAGE) on June 24, 2026. The transaction was not part of a pre-planned trading program and the shares were acquired at an unspecified price. This insider buying comes as the company's stock traded near $3.42 on Saturday.
Insider Buying and Selling at Niagen Bioscience, Inc.
On June 24, 2026, multiple insiders, including Jaksch Frank JR, Ng Wang Yu Gary, Cohen Ann, Patrick Kristin, Rubin Steven, and Shahbazi Hamed, each bought 31,746 shares of Niagen Bioscience. These purchases were not conducted under Rule 10b5-1 plans.
Other Institutional Activity in Niagen Bioscience
Institutional investors have been active in Niagen Bioscience. BlackRock, Inc. reduced its holdings by 204,090 shares, ending with 3,871,619 shares valued at approximately $17.1 million. SteelPeak Wealth, LLC opened a new position with 3,373,000 shares worth about $14.9 million. Arrowstreet Capital, Limited Partnership increased its stake by 761,685 shares, resulting in 2,378,437 shares valued at approximately $10.5 million. Vanguard Capital Management LLC also opened a new position with 2,149,277 shares worth about $9.5 million. Lastly, Tieton Capital Management, LLC added 384,062 shares, bringing its total to 2,029,155 shares valued at $8.9 million.
Niagen Bioscience, Inc. Stock Up 4.0%
Shares of Niagen Bioscience, Inc. traded near $3.42 on Saturday. The company has a market capitalization of about $272.4 million, with a P/E ratio of 16.3 and a forward P/E of 10.7. Its beta is 2.06, indicating higher volatility compared to the market. The stock's 52-week range is between $3.29 and $14.69, with a 50-day moving average of $3.99 and a 200-day moving average of $5.83. Niagen has a current ratio of 4.61 and a quick ratio of 3.48, with a debt-to-equity ratio of 3.13.
$NAGE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 11, 2026, HC Wainwright & Co. maintained a buy rating on Niagen Bioscience with a price target of $11.0. Canaccord Genuity also maintained its buy rating, setting a target of $10.0 on May 5, 2026. The consensus among analysts is a buy recommendation, with a mean target price of $12.6 based on five analyst opinions.
About Niagen Bioscience
Niagen Bioscience, Inc. is a biotechnology company based in Los Angeles, California. It focuses on developing products for healthy aging, including dietary supplements and pharmaceutical-grade ingredients. The company distributes its products through various channels, including its e-commerce platform, Amazon, and specialty retailers. Led by CEO Robert N. Fried, Niagen employs 117 people and was formerly known as ChromaDex Corporation.
Bottom Line
Insider buying by Jaksch Frank JR and other executives signals confidence in Niagen Bioscience's future. The company's stock is closely watched by investors due to its innovative products in the biotechnology sector. Institutional activity and analyst ratings provide further insights into market sentiment, but remember that these insider transactions are disclosed after the fact and may not reflect current positions.
Get Niagen Bioscience, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NAGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.